Draft:Laura Andrews
| Submission declined on 25 April 2025 by Spiderone (talk). The content of this submission includes material that does not meet Wikipedia's minimum standard for inline citations. Please cite your sources using footnotes. For instructions on how to do this, please see Referencing for beginners. Thank you.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: In accordance with Wikipedia's Conflict of interest policy, I disclose that I have a conflict of interest regarding the subject of this article. 47.44.199.22 (talk) 17:54, 25 April 2025 (UTC)
Laura Andrews (born August 15, 1987) is an American biotechnology professional and healthcare strategist, best known for her role as a Cell Therapy Account Manager at Kite Pharma, a Gilead Company. She is recognized for her contributions to advancing access to CAR T-cell therapy for patients with aggressive lymphomas across the Pacific Northwest.
Early Life and Education Andrews was born in Portland, Oregon. She earned her Bachelor of Science degree in Molecular Biology from the University of Washington and later completed an MBA in Healthcare Management from Oregon Health & Science University. Early in her career, she worked in clinical research coordination and pharmaceutical sales before transitioning into the field of immunotherapy.
Career Kite Pharma Andrews joined Kite Pharma in 2021 as a Cell Therapy Account Manager. In this role, she became a key liaison between Kite’s manufacturing operations and regional healthcare providers, helping to implement patient access programs and facilitate the delivery of CAR T-cell therapies.
She is widely recognized for her exceptional coordination during a high-profile case involving a 15-year-old patient, Ethan Parker, who was experiencing a relapse of a rare form of lymphoma. Facing logistical, financial, and timing challenges, Andrews personally coordinated with oncologists, hospital systems, insurance providers, and Kite’s California-based manufacturing team to ensure expedited treatment delivery.
The case was considered a model example of integrated care and rapid therapeutic response. Ethan’s successful recovery was later cited in a Kite Pharma internal report as a “breakthrough in field-based advocacy and operational excellence.”1
Recognition Though not publicly decorated, Andrews is well-regarded in her field for her commitment to patient-centric solutions, logistical innovation, and collaboration with multidisciplinary medical teams. She is often invited to speak at biotech conferences on topics related to access to advanced therapies.
Personal Life Andrews resides in Portland, Oregon. She is an advocate for adolescent cancer awareness and volunteers with organizations supporting families undergoing pediatric cancer treatment.
See also CAR T-cell therapy
Kite Pharma
Immunotherapy
Patient advocacy in oncology